← 產業報告目錄

Digital Pathology Market by Product (Brightfield Scanner, Enterprise Software, Storage System), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), Indication (Onco, Hemo), End User (Pharma & Biotech, Hospital) Al- Global Forecast to 2031

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2026-06-24頁數 482報告編號 HIT2608

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global digital pathology market is expected to grow steadily from USD 1.58 billion in 2026 to USD 2.86 billion by 2031, at a CAGR of 12.5% during the forecast period. The major market driver is the increasing adoption of technologies such as AI, machine learning, cloud-based platforms, and whole-slide imaging systems in pathology practices. Widespread acceptance of digitalization in laboratories and hospitals within the healthcare sector is one of the most significant drivers of market growth. Digital pathology involves scanning, storage, and analysis of tissue slides using digital methods, thereby reducing reliance on microscopy. This improves workflow efficiency and helps pathologists share cases more easily, enabling faster, more accurate diagnosis. “Brightfield scanners are projected to form the largest segment among whole-slide imaging scanners in the digital pathology market” Based on whole-slide imaging scanners, brightfield scanners are expected to dominate the market share during the forecast period. Brightfield scanners are expected to be the dominant segment, mainly because brightfield scanning technology is one of the most widely adopted and standardized technologies for routine pathology workflows in hospitals and diagnostic laboratories. Brightfield scanners are usually employed to produce digital images of stained tissue slides, such as hematoxylin and eosin (H&E) stained slides. The digital images produced by brightfield scanners resemble those that pathologists see under a microscope. Due to this reason, the adoption of brightfield scanners has been relatively easy. High accuracy of brightfield scanners has been another important driver for growth in the market. “By Type, human pathology accounted for the highest share of the digital pathology market” Based on the type, human pathology accounted for the highest share due to the growing prevalence of chronic and complicated disorders such as cancer. With the growing number of cancer patients, cardiovascular diseases, and other chronic conditions in the global population, there has been a rise in the amount of tissue analysis in hospitals and diagnostic labs. Therefore, there is a high demand for quick and reliable diagnosis methods, which is leading to a rapid adoption of digital pathology in human health care. The use of advanced technologies such as imaging and Artificial Intelligence (AI)-based diagnostic tools is another factor that is fueling the market. Such technologies aid pathologists in analyzing slides faster, recognizing abnormalities, and decision-making in complicated cases. “APAC to witness the highest growth rate during the forecast period.” In this report, the digital pathology market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The digital pathology market in APAC is projected to register the highest CAGR during the forecast period. The growth in the APAC market is mainly driven by an increasing focus on digital transformation in hospitals and diagnostic laboratories. Many healthcare systems in the region are transitioning from traditional microscopy to digital pathology platforms, enabling faster image sharing, remote consultation, and improved diagnostic accuracy. This shift is helping hospitals handle rising patient volumes more efficiently. Government initiatives are also playing a major role in market growth. Several countries in the region are promoting digital health adoption through healthcare regulations, funding programs, and national health modernization plans. These initiatives are encouraging hospitals and laboratories to adopt digital pathology systems, especially for cancer diagnosis and large-scale screening programs. The breakdown of primary participants is as mentioned below: • By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20% • By Designation - C-level: 35%, Director-level: 25%, and Others: 40% • By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%. Danaher Corporation (US) & F. Hoffmann-La Roche Ltd (Switzerland) are some of the key players in the digital pathology market • The study includes an in-depth competitive analysis of these key players in the digital pathology market, with their company profiles, recent developments, and key market strategies. Research Coverage This research report categorizes the digital pathology market by product (hardware, software, storage systems) by type (human pathology, and veterinary pathology), by technology (conventional digital pathology, AI- enabled digital pathology), by application (clinical diagnostics, pre-clinical research, clinical trials, Telepathology, Academic & Translational Research, Education & Training, Others), by therapeutic area (oncology, hematology, gastrointestinal diseases, infectious diseases, neurology, others), by end-user (hospitals & health systems, diagnostic & reference laboratories, veterinary laboratories, pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutes, others), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the digital pathology market. A detailed analysis of the key industry players has been conducted to provide insights into their business overview, solutions, key strategies, contracts, partnerships, and agreements. new product & service launches, mergers and acquisitions, and recent developments associated with the digital pathology market. This report covers competitive analysis of upcoming startups in the digital pathology market ecosystem. Reasons to buy this report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the digital pathology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. The report provides insights into the following pointers: • Analysis of key drivers (AI-enabled digital pathology improving laboratory throughput, workflow efficiency, and diagnostic accuracy; rising burden of cancer and other chronic diseases increasing pathology testing volumes; expanding adoption of digital pathology in drug discovery, biomarker validation, and clinical research, etc.), restraints (high initial capital investment for scanners, software platforms, and storage infrastructure; data interoperability issues with legacy laboratory and healthcare information systems), opportunities (affordable scanner development enabling adoption in low-resource settings; growth of cloud-native digital pathology platforms and SaaS-based deployment models, etc.), challenges (algorithm validation, explainability, and clinical trust in AI-assisted diagnostics; data privacy, cybersecurity, and patient information protection concerns, etc.) • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the digital pathology market • Market Development: Comprehensive information about lucrative markets – the report analyses the digital pathology market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the digital pathology market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Koninklijke Philips N.V. (Netherlands), Sectra AB (Sweden), Hamamatsu Photonics (Japan), Fujifilm Holdings Corporation (Japan), among others, in the digital pathology market
目錄 Table of Contents
1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 41 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 41 1.3.2 INCLUSIONS & EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 43 1.3.4 CURRENCY CONSIDERED 43 1.4 STAKEHOLDERS 44 1.5 SUMMARY OF CHANGES 44 2 EXECUTIVE SUMMARY 46 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 46 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 48 2.3 DISRUPTIVE TRENDS SHAPING MARKET 49 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 50 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 51 3 PREMIUM INSIGHTS 52 3.1 DIGITAL PATHOLOGY MARKET OVERVIEW 52 3.2 DIGITAL PATHOLOGY MARKET, BY PRODUCT & REGION 53 3.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT 54 4 MARKET OVERVIEW 55 4.1 INTRODUCTION 55 4.2 MARKET DYNAMICS 56 4.2.1 DRIVERS 56 4.2.1.1 AI-enabled digital pathology improving laboratory throughput, workflow efficiency, and diagnostic accuracy 56 4.2.1.2 Rising burden of cancer and other chronic diseases 57 4.2.1.3 Expanding adoption of digital pathology in drug discovery, biomarker validation, and clinical research 59 4.2.1.4 Growing adoption of computational pathology and advanced image analysis technologies 60 4.2.1.5 Increasing shortage of pathologists driving laboratory digitization and workflow automation 61 4.2.1.6 Rising adoption of telepathology and remote diagnostic workflows 61 4.2.1.7 Growing integration of digital pathology with EHR, PACS, and laboratory information systems 62 4.2.1.8 National cancer screening programs and healthcare digitalization initiatives 62 4.2.2 RESTRAINTS 63 4.2.2.1 High initial capital investment for scanners, software platforms, and storage infrastructure 63 4.2.2.2 Data interoperability issues with legacy laboratory and healthcare information systems 64 4.2.2.3 Regulatory and reimbursement uncertainties across key markets 64 4.2.2.4 Large-scale image storage, archiving, and data management requirements 65 4.2.2.5 Limited standardization across digital pathology workflows, image formats, and deployment practices 66 4.2.3 OPPORTUNITIES 66 4.2.3.1 Growing adoption of digital biomarkers in drug development and clinical research 66 4.2.3.2 Increasing utilization of companion diagnostics and precision oncology applications 67 4.2.3.3 Growth of cloud-native digital pathology platforms and SaaS-based deployment models 68 4.2.3.4 Affordable scanner development enabling adoption in low-resource settings 69 4.2.4 CHALLENGES 69 4.2.4.1 Shortage of skilled pathologists and technicians 69 4.2.4.2 Algorithm validation, explainability, and clinical trust in Al-assisted diagnostics 70 4.2.4.3 Data privacy, cybersecurity, and patient information protection concerns 70 4.2.4.4 Integration complexity across heterogeneous healthcare IT environments 71 4.3 UNMET NEEDS AND WHITE SPACES 71 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 73 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74 5 INDUSTRY TRENDS 75 5.1 PORTER’S FIVE FORCES ANALYSIS 75 5.1.1 THREAT OF NEW ENTRANTS 76 5.1.2 THREAT OF SUBSTITUTES 76 5.1.3 BARGAINING POWER OF SUPPLIERS 76 5.1.4 BARGAINING POWER OF BUYERS 76 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 76 5.2 MACROECONOMIC INDICATORS 76 5.2.1 INTRODUCTION 76 5.2.2 GDP TRENDS AND FORECAST 77 5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 77   5.3 VALUE CHAIN ANALYSIS 78 5.3.1 RESEARCH & PRODUCT DEVELOPMENT 78 5.3.2 COMPONENT AND TECHNOLOGY INFRASTRUCTURE 79 5.3.3 PLATFORM DEVELOPMENT AND INTEGRATION 79 5.3.4 DISTRIBUTION 79 5.3.5 MARKETING AND SALES 79 5.3.6 POST-SALE SERVICES 79 5.4 ECOSYSTEM ANALYSIS 79 5.5 PRICING ANALYSIS 81 5.5.1 INDICATIVE PRICING FOR DIGITAL PATHOLOGY PRODUCTS, BY KEY PLAYERS (2025) 81 5.5.2 INDICATIVE PRICING FOR DIGITAL PATHOLOGY PRODUCTS, BY REGION (2025) 82 5.6 TRADE ANALYSIS 83 5.6.1 IMPORT DATA (HS CODE 901180) 83 5.6.2 EXPORT DATA (HS CODE 901180) 84 5.7 KEY CONFERENCES AND EVENTS, 2026–2027 85 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 86 5.9 INVESTMENT AND FUNDING SCENARIO 87 5.10 CASE STUDY ANALYSIS 88 5.11 IMPACT OF 2025 US TARIFF – DIGITAL PATHOLOGY MARKET 89 5.11.1 INTRODUCTION 89 5.11.2 KEY TARIFF RATES 89 5.11.3 PRICE IMPACT ANALYSIS 90 5.11.4 IMPACT ON COUNTRY/REGION 91 5.11.4.1 US 91 5.11.4.2 Europe 91 5.11.4.3 Asia Pacific 92 5.11.5 IMPACT ON END USERS 92 5.11.5.1 Hospitals and health systems 92 5.11.5.2 Diagnostic and reference laboratories 92 5.11.5.3 Veterinary laboratories 92 5.11.5.4 Pharmaceutical and biotechnology companies 93 5.11.5.5 Contract research organizations 93 5.11.5.6 Academic and research institutes 93 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 94 6.1 KEY EMERGING TECHNOLOGIES 94 6.1.1 CLOUD STORAGE & ARCHIVING 94 6.1.2 WHOLE SLIDE IMAGING (WSI) SCANNERS 94 6.1.3 IMAGE MANAGEMENT SYSTEMS 94 6.1.4 AI-ENABLED IMAGE ANALYSIS & COMPUTATIONAL PATHOLOGY PLATFORMS 95 6.1.5 COMPLEMENTARY TECHNOLOGIES 95 6.1.5.1 LIS, EHR, and PACS integration 95 6.1.5.2 Digital biomarker platform 96 6.1.5.3 Companion diagnostic platforms 96 6.1.5.4 Telepathology & remote collaboration platforms 96 6.1.6 ADJACENT TECHNOLOGIES 97 6.1.6.1 Genomic sequencing 97 6.1.6.2 Multi-omics platforms 97 6.1.6.3 Precision medicine platforms 97 6.2 TECHNOLOGY/PRODUCT ROADMAP 98 6.3 PATENT ANALYSIS 98 6.3.1 PATENT PUBLICATION TRENDS FOR DIGITAL PATHOLOGY MARKET 99 6.3.2 DIGITAL PATHOLOGY PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS 100 6.4 FUTURE APPLICATIONS 103 6.4.1 AI-DRIVEN DIAGNOSTIC DECISION SUPPORT 103 6.4.2 PRECISION MEDICINE & DIGITAL BIOMARKER DEVELOPMENT 103 6.4.3 INTEGRATED PATHOLOGY FOR DRUG DEVELOPMENT & CLINICAL RESEARCH 103 6.5 IMPACT OF GEN AI IN DIGITAL PATHOLOGY MARKET 104 6.5.1 INTRODUCTION 104 6.5.2 MARKET POTENTIAL OF AI/GEN AI IN DIGITAL PATHOLOGY MARKET 105 6.5.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 106 6.5.3.1 AI-Powered Computational Pathology for Biomarker Discovery at PathAI 106 6.5.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 107 6.5.4.1 AI & computational pathology software market 107 6.5.4.2 Telepathology & remote collaboration market 107 6.5.4.3 Digital biomarker market 108 6.5.5 USER READINESS AND IMPACT ASSESSMENT 108 6.5.5.1 User readiness 108 6.5.5.2 Hospitals & health systems 108 6.5.5.3 Diagnostic & reference laboratories 108 6.5.5.4 Veterinary laboratories 108 6.5.5.5 Pharmaceutical & biotechnology companies 108 6.5.5.6 Contract research organizations (CROs) 109 6.5.5.7 Academic & research institutes 109 6.5.5.8 Impact assessment 109 6.5.5.9 User A: Hospitals and health systems 109 6.5.5.9.1 Implementation 109 6.5.5.9.2 Impact 109   6.5.5.10 User B: Diagnostic & reference laboratories 110 6.5.5.10.1 Implementation 110 6.5.5.10.2 Impact 110 6.5.5.11 User C: Veterinary laboratories 110 6.5.5.11.1 Implementation 110 6.5.5.11.2 Impact 110 6.5.5.12 User D: Pharmaceutical & biotechnology companies 110 6.5.5.12.1 Implementation 110 6.5.5.12.2 Impact 111 6.5.5.13 User E: Contract Research Organizations 111 6.5.5.13.1 Implementation 111 6.5.5.13.2 Impact 111 6.5.5.14 User F: Academic & research institutes 111 6.5.5.14.1 Implementation 111 6.5.5.14.2 Impact 111 7 REGULATORY LANDSCAPE 112 7.1 REGIONAL REGULATIONS AND COMPLIANCE 112 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113 7.1.2 REGULATORY FRAMEWORK 118 7.1.2.1 North America 118 7.1.2.2 Europe 119 7.1.2.3 Asia Pacific 119 7.1.2.4 Latin America 120 7.1.2.5 Middle East & Africa 121 7.1.3 INDUSTRY STANDARDS 121 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 123 8.1 INTRODUCTION 123 8.2 DECISION-MAKING PROCESS 123 8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 123 8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 124 8.3.2 BUYING CRITERIA 125 8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 126 8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 127 8.5.1 UNMET NEEDS 127 8.5.2 END USER EXPECTATIONS 129 8.6 MARKET PROFITABILITY 130   9 DIGITAL PATHOLOGY MARKET, BY PRODUCT 131 9.1 INTRODUCTION 132 9.2 HARDWARE 132 9.2.1 DIGITIZATION OF PATHOLOGY WORKFLOWS AND INCREASING INSTALLATION OF WHOLE-SLIDE IMAGING SYSTEMS TO BOOST MARKET 132 9.2.2 WHOLE SLIDE IMAGING SCANNERS 134 9.2.2.1 Increasing pathology workloads & need for remote consultation driving demand 134 9.2.2.2 Brightfield scanners 137 9.2.2.2.1 Cost-efficient features to boost demand 137 9.2.2.3 Fluorescence scanners 138 9.2.2.3.1 Ability to detect cellular structures and biomarkers to fuel uptake 138 9.2.2.4 Other scanners 139 9.2.3 WORKSTATIONS & VIEWING SYSTEMS 140 9.2.3.1 Rising demand for digital pathology visualization and collaboration tools 140 9.2.4 PERIPHERALS & ACCESSORIES 141 9.2.4.1 Growing laboratory automation and workflow digitization support adoption of pathology accessories 141 9.3 SOFTWARE 142 9.3.1 INCREASING DEMAND FOR REMOTE WORK AND CONSULTATIONS TO BOOST DEMAND 142 9.3.1.1 Enterprise digital pathology solutions/platforms 144 9.3.1.1.1 Growing enterprise-wide digital transformation initiatives drive adoption of integrated pathology platforms 144 9.3.1.2 Image Management Software 145 9.3.1.2.1 Increasing digital slide volumes drive demand for scalable image management solutions 145 9.3.1.3 Image analysis software 146 9.3.1.3.1 Ability to automate quantitative evaluation to support market growth 146 9.3.1.4 AI & computational pathology software 147 9.3.1.4.1 Growing adoption of AI-assisted diagnostics drives rapid market expansion 147 9.4 STORAGE SYSTEMS 148 9.4.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET 148 9.4.1.1 On-premise Storage 150 9.4.1.1.1 Data security, regulatory compliance, and direct infrastructure control support continued adoption 150 9.4.1.2 Cloud Storage 151 9.4.1.2.1 Scalability, remote accessibility, and cost-efficient data management driving growth of cloud-based storage solutions 151   9.4.1.3 Hybrid storage 152 9.4.1.3.1 Balance of performance, scalability, and compliance requirements accelerate adoption 152 10 DIGITAL PATHOLOGY MARKET, BY TYPE 154 10.1 INTRODUCTION 155 10.2 HUMAN PATHOLOGY 155 10.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET 155 10.3 VETERINARY PATHOLOGY 156 10.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH 156 11 DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY 158 11.1 INTRODUCTION 159 11.2 CONVENTIONAL DIGITAL PATHOLOGY 159 11.2.1 DIGITIZATION OF PATHOLOGY WORKFLOWS AND ADOPTION OF WHOLE-SLIDE IMAGING TECHNOLOGIES DRIVES MARKET 159 11.3 AI-ENABLED DIGITAL PATHOLOGY 160 11.3.1 ADOPTION OF AI AND COMPUTATIONAL PATHOLOGY TECHNOLOGIES ACCELERATES TRANSITION TO DATA-DRIVEN DIAGNOSTICS 160 12 DIGITAL PATHOLOGY MARKET, BY APPLICATION 162 12.1 INTRODUCTION 163 12.2 CLINICAL DIAGNOSTICS 163 12.2.1 INCREASING CANCER INCIDENCE & GROWING ADOPTION OF AI-FOR ASSISTED DIAGNOSTICS TO DRIVE MARKET 163 12.3 PRE-CLINICAL RESEARCH 165 12.3.1 GROWTH SUPPORTED BY EXPANDING PHARMACEUTICAL AND BIOTECHNOLOGY R&D INVESTMENTS 165 12.3.2 DRUG DISCOVERY & EFFICACY STUDIES 166 12.3.2.1 Growing pharmaceutical R&D investments and rising demand for accelerated therapeutic development 166 12.3.3 TOXICOLOGY AND SAFETY ASSESSMENT 167 12.3.3.1 Increasing regulatory testing requirements and adoption of AI-enabled pathology analysis for standardized safety evaluations to drive market 167 12.3.4 BIOMARKER DISCOVERY & VALIDATION 168 12.3.4.1 Increasing adoption of personalized medicine to boost market 168 12.3.5 OTHER PRE-CLINICAL RESEARCH 169 12.4 CLINICAL TRIALS 170 12.4.1 USE FOR CENTRALIZED REVIEW, PATIENT STRATIFICATION, AND BIOMARKER-BASED CLINICAL STUDIES 170 12.5 TELEPATHOLOGY 171 12.5.1 INCREASING DEMAND FOR REMOTE DIAGNOSTICS AND GROWING SHORTAGE OF PATHOLOGISTS WORLDWIDE TO BOOST GROWTH 171   12.6 ACADEMIC & TRANSLATIONAL RESEARCH 172 12.6.1 GROWTH SUPPORTED BY EXPANDING COMPUTATIONAL PATHOLOGY RESEARCH AND INVESTMENTS IN PRECISION MEDICINE 172 12.7 EDUCATION & TRAINING 173 12.7.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH 173 12.8 OTHER APPLICATIONS 174 13 DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA 176 13.1 INTRODUCTION 177 13.2 ONCOLOGY 177 13.2.1 INCREASING ADOPTION OF PRECISION MEDICINE AND DEMAND FOR AI-ASSISTED CANCER DIAGNOSTICS TO BOOST MARKET 177 13.3 HEMATOLOGY 179 13.3.1 IMPLEMENTATION OF AI-POWERED SOLUTIONS FOR BONE MARROW AND BLOOD CELL ANALYSIS TO DRIVE MARKET 179 13.4 GASTROINTESTINAL DISEASE 180 13.4.1 GROWING ADOPTION OF DIGITAL PATHOLOGY SOLUTIONS FOR EARLY DISEASE DETECTION AND DIAGNOSIS TO DRIVE MARKET 180 13.5 INFECTIOUS DISEASE 181 13.5.1 GROWING NEED FOR RAPID AND ACCURATE TISSUE-BASED DIAGNOSTICS TO PROPEL MARKET 181 13.6 NEUROLOGY 182 13.6.1 GROWING NEED FOR RAPID AND ACCURATE TISSUE-BASED DIAGNOSTICS DRIVES GROWTH 182 13.7 OTHERS THERAPEUTIC AREAS 183 14 DIGITAL PATHOLOGY MARKET, BY END USER 185 14.1 INTRODUCTION 186 14.2 HOSPITALS & HEALTH SYSTEMS 186 14.2.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND 186 14.3 DIAGNOSTICS LABORATORIES & REFERENCE LABORATORIES 188 14.3.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 188 14.4 VETERINARY LABORATORIES 189 14.4.1 TECHNOLOGICAL ADVANCEMENTS IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE SUPPORT MARKET GROWTH 189 14.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 190 14.5.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET 190 14.6 CONTRACT RESEARCH ORGANIZATION 192 14.6.1 DEMAND FOR OUTSOURCED RESEARCH AND BIOMARKER ANALYSIS SUPPORTS ADOPTION 192   14.7 ACADEMIC & RESEARCH INSTITUTES 193 14.7.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH 193 14.8 OTHER END USERS 194 15 DIGITAL PATHOLOGY MARKET, BY REGION 196 15.1 INTRODUCTION 197 15.2 NORTH AMERICA 197 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 198 15.2.2 US 204 15.2.2.1 Favorable reimbursements for diagnostics to drive market 204 15.2.3 CANADA 212 15.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market 212 15.3 EUROPE 218 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 218 15.3.2 GERMANY 224 15.3.2.1 High healthcare expenditure and supportive research initiatives to drive market 224 15.3.3 UK 230 15.3.3.1 Government funding investments for pathology services to fuel market 230 15.3.4 FRANCE 237 15.3.4.1 Increasing government funding and favorable insurance system to drive adoption 237 15.3.5 ITALY 242 15.3.5.1 Integration of AI & ML to support market growth 242 15.3.6 SPAIN 247 15.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand 247 15.3.7 SWEDEN 252 15.3.7.1 Increasing prevalence of chronic diseases to support market growth 252 15.3.8 REST OF EUROPE 258 15.4 ASIA PACIFIC 263 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 264 15.4.2 CHINA 269 15.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market 269 15.4.3 JAPAN 275 15.4.3.1 Advanced healthcare infrastructure to support market growth 275 15.4.4 INDIA 280 15.4.4.1 High cancer incidence and rapid healthcare digitization supporting strong growth in digital pathology solutions 280   15.4.5 AUSTRALIA 286 15.4.5.1 National digital health initiatives and geographically distributed healthcare networks driving demand 286 15.4.6 SOUTH KOREA 291 15.4.6.1 Regional leadership in digital pathology and AI diagnostics supporting market expansion 291 15.4.7 REST OF ASIA PACIFIC 296 15.5 LATIN AMERICA 301 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 301 15.5.2 BRAZIL 307 15.5.2.1 Biopharma clinical trial demand and Conecte SUS integration catalyzing digital pathology infrastructure 307 15.5.3 MEXICO 312 15.5.3.1 Private sector healthcare expansion and pharmaceutical manufacturing drive digital pathology adoption 312 15.5.4 REST OF LATIN AMERICA 317 15.6 MIDDLE EAST & AFRICA 322 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 322 15.6.2 GCC COUNTRIES 328 15.6.2.1 Saudi Arabia 333 15.6.2.1.1 Vision 2030 health transformation and AI national strategy anchoring pathology digitization investment 333 15.6.2.2 UAE 338 15.6.2.2.1 National AI Strategy 2031 and DHA Digital Health Ecosystem positions country as regional pathology hub 338 15.6.2.3 Other GCC countries 343 15.6.3 SOUTH AFRICA 347 15.6.3.1 Growing demand for diagnostic efficiency and healthcare digitalization initiatives to boost market 347 15.6.4 REST OF MIDDLE EAST & AFRICA 352 16 COMPETITIVE LANDSCAPE 358 16.1 OVERVIEW 358 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 358 16.3 REVENUE ANALYSIS, 2021–2025 361 16.4 MARKET SHARE ANALYSIS, 2025 361 16.5 BRAND COMPARISON 365 16.6 COMPANY VALUATION AND FINANCIAL METRICS 366 16.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 367 16.7.1 STARS 367 16.7.2 EMERGING LEADERS 367 16.7.3 PERVASIVE PLAYERS 367 16.7.4 PARTICIPANTS 367 16.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 369 16.7.5.1 Company footprint 369 16.7.5.2 Region footprint 370 16.7.5.3 Product footprint 371 16.7.5.4 Application footprint 372 16.7.5.5 End user footprint 373 16.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 374 16.8.1 PROGRESSIVE COMPANIES 374 16.8.2 RESPONSIVE COMPANIES 374 16.8.3 DYNAMIC COMPANIES 374 16.8.4 STARTING BLOCKS 374 16.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 376 16.8.5.1 List of startups/SMES 376 16.9 COMPETITIVE SCENARIO 378 16.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS 378 16.9.2 DEALS 379 16.9.3 EXPANSIONS 381 16.9.4 OTHER DEVELOPMENTS 381 17 COMPANY PROFILES 382 17.1 KEY COMPANIES 382 17.1.1 DANAHER CORPORATION 382 17.1.1.1 Business overview 382 17.1.1.2 Products offered 384 17.1.1.3 Recent developments 384 17.1.1.3.1 Product launches & enhancements 384 17.1.1.3.2 Deals 385 17.1.1.3.3 Other developments 386 17.1.1.4 MnM view 386 17.1.1.4.1 Key strengths 386 17.1.1.4.2 Strategic choices 387 17.1.1.4.3 Weaknesses and competitive threats 387 17.1.2 HOFFMANN-LA ROCHE LTD. 388 17.1.2.1 Business overview 388 17.1.2.2 Products offered 389 17.1.2.3 Recent developments 390 17.1.2.3.1 Product launches & approvals 390 17.1.2.3.2 Deals 391 17.1.2.4 MnM view 391 17.1.2.4.1 Key strengths 391 17.1.2.4.2 Strategic choices 392 17.1.2.4.3 Weaknesses and competitive threats 392   17.1.3 KONINKLIJKE PHILIPS N.V. 393 17.1.3.1 Business overview 393 17.1.3.2 Products offered 394 17.1.3.3 Recent developments 395 17.1.3.3.1 Product launches & approvals 395 17.1.3.3.2 Deals 396 17.1.3.4 MnM view 397 17.1.3.4.1 Key strengths 397 17.1.3.4.2 Strategic choices 397 17.1.3.4.3 Weaknesses and competitive threats 397 17.1.4 SECTRA AB 398 17.1.4.1 Business overview 398 17.1.4.2 Products offered 399 17.1.4.3 Recent developments 400 17.1.4.3.1 Deals 400 17.1.4.3.2 Other developments 402 17.1.4.4 MnM view 402 17.1.4.4.1 Key strengths 402 17.1.4.4.2 Strategic choices 402 17.1.4.4.3 Weaknesses and competitive threats 402 17.1.5 HAMAMATSU PHOTONICS K.K. 403 17.1.5.1 Business overview 403 17.1.5.2 Products offered 404 17.1.5.3 Recent developments 405 17.1.5.3.1 Deals 405 17.1.5.4 MnM view 405 17.1.5.4.1 Key strengths 405 17.1.5.4.2 Strategic choices 406 17.1.5.4.3 Weaknesses and competitive threats 406 17.1.6 QUANTERIX CORPORATION 407 17.1.6.1 Business overview 407 17.1.6.2 Products offered 408 17.1.6.3 Recent developments 409 17.1.6.3.1 Product launches 409 17.1.6.4 Recent developments 409 17.1.6.4.1 Deals 409 17.1.7 FUJIFILM HOLDINGS CORPORATION 410 17.1.7.1 Business overview 410 17.1.7.2 Products offered 411 17.1.7.3 Recent developments 412 17.1.7.3.1 Deals 412   17.1.8 HOLOGIC, INC. 414 17.1.8.1 Business overview 414 17.1.8.2 Products offered 415 17.1.8.3 Recent developments 416 17.1.8.3.1 Product approvals 416 17.1.9 3DHISTECH LTD. 417 17.1.9.1 Business overview 417 17.1.9.2 Products offered 418 17.1.9.3 Recent developments 420 17.1.9.3.1 Product launches & enhancements 420 17.1.9.3.2 Other developments 420 17.1.10 APOLLO ENTERPRISE IMAGING CORP. 421 17.1.10.1 Business overview 421 17.1.10.2 Products offered 421 17.1.10.3 Recent developments 422 17.1.10.3.1 Product enhancements 422 17.1.10.3.2 Deals 422 17.1.11 HURON TECHNOLOGIES INTERNATIONAL INC. 423 17.1.11.1 Business overview 423 17.1.11.2 Products offered 423 17.1.11.2.1 Deals 424 17.1.12 INDICA LABS, LLC. 425 17.1.12.1 Business overview 425 17.1.12.2 Products offered 425 17.1.12.3 Recent developments 426 17.1.12.3.1 Product launches & approvals 426 17.1.12.3.2 Deals 427 17.1.13 OPTRASCAN 429 17.1.13.1 Business overview 429 17.1.13.2 Products offered 429 17.1.13.3 Recent developments 430 17.1.13.3.1 Product launches & approvals 430 17.1.13.3.2 Deals 430 17.1.14 GLENCOE SOFTWARE, INC. 431 17.1.14.1 Business overview 431 17.1.14.2 Products offered 431 17.1.14.3 Recent developments 432 17.1.14.3.1 Product enhancements 432 17.1.15 AIFORIA 433 17.1.15.1 Business overview 433 17.1.15.2 Products offered 433 17.1.15.3 Recent developments 434 17.1.15.3.1 Product launches 434 17.1.15.3.2 Deals 434 17.1.15.3.3 Expansions 436 17.1.16 PAIGE AI, INC. 437 17.1.16.1 Business overview 437 17.1.16.2 Products offered 437 17.1.16.3 Recent developments 438 17.1.16.3.1 Product launches & enhancements 438 17.1.16.3.2 Deals 439 17.1.17 PROSCIA INC. 442 17.1.17.1 Business overview 442 17.1.17.2 Products offered 442 17.1.17.3 Recent developments 443 17.1.17.3.1 Product enhancements & approvals 443 17.1.17.3.2 Deals 444 17.1.17.3.3 Other developments 445 17.1.18 EVIDENT 446 17.1.18.1 Business overview 446 17.1.18.2 Products offered 446 17.1.18.3 Recent developments 447 17.1.18.3.1 Product launches 447 17.1.18.3.2 Deals 447 17.2 OTHER PLAYERS 449 17.2.1 PATHAI, INC. 449 17.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD. 450 17.2.3 MIKROSCAN TECHNOLOGIES, INC. 451 17.2.4 MOTIC DIGITAL PATHOLOGY 452 17.2.5 MORPHLE LABS INC. 453 17.2.6 GRUNDIUM OY 454 17.2.7 CURIOSIS INC. 455 18 RESEARCH METHODOLOGY 456 18.1 RESEARCH APPROACH 456 18.1.1 SECONDARY RESEARCH 457 18.1.1.1 Key data from secondary sources 458 18.1.2 PRIMARY RESEARCH 458 18.1.2.1 Key data from primary sources 460 18.1.2.2 Breakdown of primaries 461 18.1.2.3 Insights from primary experts 461 18.2 RESEARCH METHODOLOGY DESIGN 462 18.3 MARKET SIZE ESTIMATION 463 18.4 MARKET BREAKDOWN DATA TRIANGULATION 468 18.5 MARKET SHARE ESTIMATION 470 18.6 STUDY ASSUMPTIONS 470 18.7 RESEARCH LIMITATIONS 471 18.7.1 METHODOLOGY-RELATED LIMITATIONS 471 18.7.2 SCOPE-RELATED LIMITATIONS 471 18.8 RISK ASSESSMENT 471 19 APPENDIX 472 19.1 DISCUSSION GUIDE 472 19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 478 19.3 CUSTOMIZATION OPTIONS 480 19.4 RELATED REPORTS 480 19.5 AUTHOR DETAILS 481
圖表清單 List of Tables & Figures
TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 44 TABLE 2 INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION) 59 TABLE 3 HEALTHCARE DATA BREACHES: ENTITIES, IMPACT, AND CAUSES (2025) 70 TABLE 4 DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES 75 TABLE 5 DIGITAL PATHOLOGY MARKET: ROLE IN ECOSYSTEM 80 TABLE 6 INDICATIVE PRICING OF DIGITAL PATHOLOGY PRODUCTS, BY KEY PLAYER (2025) 82 TABLE 7 INDICATIVE PRICING OF WHOLE SLIDE IMAGING SCANNERS, BY REGION (2025) 83 TABLE 8 IMPORT DATA FOR HS CODE 901180, BY COUNTRY, 2021–2025 (USD THOUSAND) 83 TABLE 9 EXPORT DATA FOR HS CODE 901180, BY COUNTRY, 2021–2025 (USD THOUSAND) 84 TABLE 10 DIGITAL PATHOLOGY: KEY CONFERENCES & EVENTS, 2026–2027 85 TABLE 11 CASE 1: ASSESSING IMAGE QUALITY: A COMPARATIVE MULTI-ASSESSMENT EVALUATION OF APERIO GT 450 DX 88 TABLE 12 CASE STUDY 2: HOW TO PROMOTE PATHOLOGY WORKFLOW EFFICIENCY 88 TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES 89 TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY MARKET 100 TABLE 15 DIGITAL PATHOLOGY MARKET: KEY PATENTS/PATENT APPLICATIONS 102 TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113 TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114 TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115 TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116 TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117 TABLE 21 REGULATORY SCENARIO IN NORTH AMERICA 118 TABLE 22 REGULATORY SCENARIO IN EUROPE 119 TABLE 23 REGULATORY SCENARIO IN ASIA PACIFIC 119 TABLE 24 REGULATORY SCENARIO IN LATIN AMERICA 120 TABLE 25 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 121 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE END USERS (%) 125 TABLE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS 126 TABLE 28 UNMET NEEDS IN DIGITAL PATHOLOGY MARKET 128 TABLE 29 END USER EXPECTATIONS IN DIGITAL PATHOLOGY MARKET 129 TABLE 30 DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 132 TABLE 31 DIGITAL PATHOLOGY HARDWARE OFFERED BY KEY MARKET PLAYERS 133 TABLE 32 DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 133 TABLE 33 DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY REGION, 2024–2031(USD MILLION) 134 TABLE 34 SCANNING MAGNIFICATION AND APPLICATIONS 135 TABLE 35 DIGITAL PATHOLOGY WHOLE SLIDE IMAGING (WSI) SCANNERS OFFERED BY KEY MARKET PLAYERS 135 TABLE 36 DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 37 DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 38 BRIGHTFIELD SCANNERS OFFERED BY KEY MARKET PLAYERS 137 TABLE 39 DIGITAL PATHOLOGY MARKET FOR BRIGHTFIELD SCANNERS, BY REGION, 2024–2031(USD MILLION) 138 TABLE 40 FLUORESCENCE SCANNERS OFFERED BY KEY MARKET PLAYERS 138 TABLE 41 DIGITAL PATHOLOGY MARKET FOR FLUORESCENCE SCANNERS, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 42 OTHER SCANNERS OFFERED BY KEY MARKET PLAYERS 139 TABLE 43 DIGITAL PATHOLOGY MARKET FOR OTHER SCANNERS, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 44 WORKSTATIONS & VIEWING SYSTEMS: OFFERED BY KEY MARKET PLAYERS 141 TABLE 45 DIGITAL PATHOLOGY MARKET FOR WORKSTATIONS & VIEWING SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 46 PERIPHERALS & ACCESSORIES OFFERED BY KEY MARKET PLAYERS 142 TABLE 47 DIGITAL PATHOLOGY MARKET FOR PERIPHERALS & ACCESSORIES, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 48 DIGITAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS 143 TABLE 49 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 143 TABLE 50 DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 51 ENTERPRISE DIGITAL PATHOLOGY SOLUTIONS/PLATFORMS OFFERED BY KEY MARKET PLAYERS 144 TABLE 52 DIGITAL PATHOLOGY MARKET FOR ENTERPRISE DIGITAL PATHOLOGY SOLUTIONS/PLATFORMS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 53 IMAGE MANAGEMENT SOFTWARE OFFERED BY KEY MARKET PLAYERS 145 TABLE 54 DIGITAL PATHOLOGY MARKET FOR IMAGE MANAGEMENT SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 146 TABLE 55 IMAGE ANALYSIS SOFTWARE OFFERED BY KEY MARKET PLAYERS 146 TABLE 56 DIGITAL PATHOLOGY MARKET FOR IMAGE ANALYSIS SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 57 AI & COMPUTATIONAL PATHOLOGY SOFTWARE OFFERED BY KEY MARKET PLAYERS 147 TABLE 58 DIGITAL PATHOLOGY MARKET FOR AI & COMPUTATIONAL PATHOLOGY SOFTWARE, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 59 DIGITAL PATHOLOGY STORAGE SYSTEMS OFFERED BY KEY MARKET PLAYERS 149 TABLE 60 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 149 TABLE 61 DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 62 DIGITAL PATHOLOGY MARKET FOR ON-PREMISE STORAGE, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 63 DIGITAL PATHOLOGY MARKET FOR CLOUD STORAGE, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 64 DIGITAL PATHOLOGY MARKET FOR HYBRID STORAGE, BY REGION, 2024–2031 (USD MILLION) 153 TABLE 65 DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 66 DIGITAL PATHOLOGY MARKET FOR HUMAN DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 156 TABLE 67 DIGITAL PATHOLOGY MARKET FOR VETERINARY DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 157 TABLE 68 DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 159 TABLE 69 DIGITAL PATHOLOGY MARKET FOR CONVENTIONAL DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 160 TABLE 70 DIGITAL PATHOLOGY MARKET FOR AI-ENABLED DIGITAL PATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 161 TABLE 71 DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 163 TABLE 72 DIGITAL PATHOLOGY MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 164 TABLE 73 DIGITAL PATHOLOGY MARKET, BY PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 165 TABLE 74 DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 75 DIGITAL PATHOLOGY MARKET FOR DRUG DISCOVERY & EFFICACY STUDIES, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 76 DIGITAL PATHOLOGY MARKET FOR TOXICOLOGY AND SAFETY ASSESSMENT, BY REGION, 2024–2031 (USD MILLION) 168 TABLE 77 DIGITAL PATHOLOGY MARKET FOR BIOMARKER DISCOVERY AND VALIDATION, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 78 DIGITAL PATHOLOGY MARKET OTHER PRE-CLINICAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 79 DIGITAL PATHOLOGY MARKET FOR CLINICAL TRIALS, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 80 DIGITAL PATHOLOGY MARKET FOR TELEPATHOLOGY, BY REGION, 2024–2031 (USD MILLION) 172 TABLE 81 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & TRANSLATIONAL RESEARCH, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 82 DIGITAL PATHOLOGY MARKET FOR EDUCATION & TRAINING, BY REGION, 2024–2031 (USD MILLION) 174 TABLE 83 DIGITAL PATHOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 84 DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 177 TABLE 85 DIGITAL PATHOLOGY MARKET FOR ONCOLOGY, BY REGION, 2024–2031 (USD MILLION) 178 TABLE 86 DIGITAL PATHOLOGY MARKET FOR HEMATOLOGY, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 87 DIGITAL PATHOLOGY MARKET FOR GASTROINTESTINAL DISEASE, BY REGION, 2024–2031 (USD MILLION) 181 TABLE 88 DIGITAL PATHOLOGY MARKET FOR INFECTIOUS DISEASE, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 89 DIGITAL PATHOLOGY MARKET FOR NEUROLOGY, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 90 DIGITAL PATHOLOGY MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 184 TABLE 91 DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 186 TABLE 92 DEPLOYMENT OF DIGITAL PATHOLOGY SOLUTIONS IN HOSPITALS & HEALTH SYSTEMS 187 TABLE 93 DIGITAL PATHOLOGY MARKET FOR HOSPITALS & HEALTH SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 94 DIGITAL PATHOLOGY MARKET FOR DIAGNOSTICS & REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 95 DIGITAL PATHOLOGY MARKET FOR VETERINARY LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 190 TABLE 96 DIGITAL PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 97 DIGITAL PATHOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 98 DIGITAL PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 99 DIGITAL PATHOLOGY MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 100 DIGITAL PATHOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION) 197 TABLE 101 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 102 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 199 TABLE 103 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 104 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 200 TABLE 105 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031(USD MILLION) 200 TABLE 106 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031(USD MILLION) 201 TABLE 107 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 201 TABLE 108 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 201 TABLE 109 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 202 TABLE 110 NORTH AMERICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 202 TABLE 111 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 203 TABLE 112 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 203 TABLE 113 CAT III - DIGITAL PATHOLOGY ADD-ON CPT CODES – EFFECTIVE 1 JANUARY 2024 205 TABLE 114 US: CANCER INCIDENCE, BY CANCER TYPE, 2022 VS. 2040 207 TABLE 115 US: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 207 TABLE 116 US: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 117 US: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 208 TABLE 118 US: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031(USD MILLION) 208 TABLE 119 US: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031(USD MILLION) 209 TABLE 120 US: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 209 TABLE 121 US: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 209 TABLE 122 US: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 210 TABLE 123 US: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 210 TABLE 124 US: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 211 TABLE 125 US: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 211 TABLE 126 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 213 TABLE 127 CANADA: FUNDING INITIATIVES FOR DIGITAL PATHOLOGY 213 TABLE 128 CANADA: KEY MACROINDICATORS 214 TABLE 129 CANADA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 214 TABLE 130 CANADA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 214 TABLE 131 CANADA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 215 TABLE 132 CANADA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031(USD MILLION) 215 TABLE 133 CANADA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031(USD MILLION) 215 TABLE 134 CANADA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 216 TABLE 135 CANADA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 216 TABLE 136 CANADA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 216 TABLE 137 CANADA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 217 TABLE 138 CANADA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 217 TABLE 139 CANADA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 218 TABLE 140 EUROPE: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 141 EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 219 TABLE 142 EUROPE: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 143 EUROPE: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 144 EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 145 EUROPE: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 146 EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 221 TABLE 147 EUROPE: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 222 TABLE 148 EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222 TABLE 149 EUROPE: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 223 TABLE 150 EUROPE: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 223 TABLE 151 EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 224 TABLE 152 GERMANY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 225 TABLE 153 GERMANY: KEY MACROINDICATORS 225 TABLE 154 GERMANY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 226 TABLE 155 GERMANY: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 156 GERMANY: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 226 TABLE 157 GERMANY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 158 GERMANY: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 159 GERMANY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 227 TABLE 160 GERMANY: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 228 TABLE 161 GERMANY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 228 TABLE 162 GERMANY: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 229 TABLE 163 GERMANY: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 229 TABLE 164 GERMANY: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 230 TABLE 165 UK: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 232 TABLE 166 UK: KEY MACROINDICATORS 232 TABLE 167 UK: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 232 TABLE 168 UK: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 169 UK: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 170 UK: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 233 TABLE 171 UK: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 172 UK: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 173 UK: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 234 TABLE 174 UK: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 175 UK: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 176 UK: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 236 TABLE 177 UK: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 236 TABLE 178 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 237 TABLE 179 FRANCE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 238 TABLE 180 FRANCE: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 181 FRANCE: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 238 TABLE 182 FRANCE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 183 FRANCE: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 184 FRANCE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 185 FRANCE: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 186 FRANCE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 240 TABLE 187 FRANCE: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 188 FRANCE: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 241 TABLE 189 FRANCE: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 190 ITALY: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 243 TABLE 191 ITALY: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 192 ITALY: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 193 ITALY: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 194 ITALY: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 195 ITALY: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 196 ITALY: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 245 TABLE 197 ITALY: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 245 TABLE 198 ITALY: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 199 ITALY: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 246 TABLE 200 ITALY: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 247 TABLE 201 SPAIN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 248 TABLE 202 SPAIN: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 203 SPAIN: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 204 SPAIN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 205 SPAIN: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 206 SPAIN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 207 SPAIN: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 250 TABLE 208 SPAIN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 250 TABLE 209 SPAIN: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 210 SPAIN: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 251 TABLE 211 SPAIN: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 212 SWEDEN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 253 TABLE 213 SWEDEN: KEY MACROINDICATORS 253 TABLE 214 SWEDEN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 254 TABLE 215 SWEDEN: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 216 SWEDEN: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 254 TABLE 217 SWEDEN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 218 SWEDEN: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 219 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 220 SWEDEN: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 256 TABLE 221 SWEDEN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 256 TABLE 222 SWEDEN: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 223 SWEDEN: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 257 TABLE 224 SWEDEN: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 258 TABLE 225 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 259 TABLE 226 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 227 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 228 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 229 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 230 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 231 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 261 TABLE 232 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 261 TABLE 233 REST OF EUROPE: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 234 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 262 TABLE 235 REST OF EUROPE: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 236 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 265 TABLE 237 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 265 TABLE 238 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 239 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 240 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 241 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 242 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 243 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 267 TABLE 244 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 245 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 246 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 268 TABLE 247 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 248 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 270 TABLE 249 CHINA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 270 TABLE 250 CHINA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 251 CHINA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 252 CHINA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 253 CHINA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 254 CHINA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 255 CHINA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272 TABLE 256 CHINA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 273 TABLE 257 CHINA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 258 CHINA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 274 TABLE 259 CHINA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 260 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 275 TABLE 261 JAPAN: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 276 TABLE 262 JAPAN: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 263 JAPAN: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 264 JAPAN: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 265 JAPAN: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 266 JAPAN: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 267 JAPAN: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 278 TABLE 268 JAPAN: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278 TABLE 269 JAPAN: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 270 JAPAN: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 279 TABLE 271 JAPAN: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 280 TABLE 272 INDIA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 281 TABLE 273 INDIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 281 TABLE 274 INDIA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 275 INDIA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 276 INDIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 277 INDIA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 278 INDIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 279 INDIA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 283 TABLE 280 INDIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 284 TABLE 281 INDIA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 282 INDIA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 285 TABLE 283 INDIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 285 TABLE 284 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 286 TABLE 285 AUSTRALIA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 286 AUSTRALIA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 287 AUSTRALIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 288 AUSTRALIA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 289 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 290 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 288 TABLE 291 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 289 TABLE 292 AUSTRALIA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 293 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 290 TABLE 294 AUSTRALIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 290 TABLE 295 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 292 TABLE 296 SOUTH KOREA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 297 SOUTH KOREA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 298 SOUTH KOREA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 299 SOUTH KOREA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 300 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 301 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 294 TABLE 302 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 294 TABLE 303 SOUTH KOREA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 304 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 295 TABLE 305 SOUTH KOREA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 296 TABLE 306 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 297 TABLE 307 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 308 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 309 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 310 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 311 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 312 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 299 TABLE 313 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 299 TABLE 314 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 315 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 300 TABLE 316 REST OF ASIA PACIFIC: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 301 TABLE 317 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 302 TABLE 318 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 302 TABLE 319 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 320 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 321 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 322 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 323 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 324 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 304 TABLE 325 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305 TABLE 326 LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 327 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 306 TABLE 328 LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 306 TABLE 329 BRAZIL: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 307 TABLE 330 BRAZIL: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 308 TABLE 331 BRAZIL: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 332 BRAZIL: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 333 BRAZIL: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 334 BRAZIL: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 335 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 336 BRAZIL: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 310 TABLE 337 BRAZIL: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 310 TABLE 338 BRAZIL: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 339 BRAZIL: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 311 TABLE 340 BRAZIL: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 341 MEXICO: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 313 TABLE 342 MEXICO: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 313 TABLE 343 MEXICO: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 344 MEXICO: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 345 MEXICO: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 346 MEXICO: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 347 MEXICO: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 348 MEXICO: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 315 TABLE 349 MEXICO: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 315 TABLE 350 MEXICO: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 351 MEXICO: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 316 TABLE 352 MEXICO: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 317 TABLE 353 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 318 TABLE 354 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 355 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 356 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 357 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 358 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 359 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 320 TABLE 360 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 320 TABLE 361 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 362 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 321 TABLE 363 REST OF LATIN AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 364 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 323 TABLE 365 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 323 TABLE 366 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 367 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 368 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 369 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 370 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 371 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 325 TABLE 372 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 326 TABLE 373 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 374 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 327 TABLE 375 MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 327 TABLE 376 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 328 TABLE 377 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 328 TABLE 378 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 379 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 380 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 381 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 382 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 383 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 330 TABLE 384 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 331 TABLE 385 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 386 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 332 TABLE 387 GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 332 TABLE 388 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 333 TABLE 389 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 390 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 391 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 392 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 393 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 394 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 335 TABLE 395 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 336 TABLE 396 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 397 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 337 TABLE 398 SAUDI ARABIA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 337 TABLE 399 UAE: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 338 TABLE 400 UAE: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 401 UAE: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 402 UAE: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 403 UAE: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 404 UAE: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 405 UAE: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 340 TABLE 406 UAE: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 341 TABLE 407 UAE: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 408 UAE: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 342 TABLE 409 UAE: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 342 TABLE 410 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 343 TABLE 411 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 412 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 413 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 414 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 415 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 416 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 345 TABLE 417 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 345 TABLE 418 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 419 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 346 TABLE 420 OTHER GCC COUNTRIES: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 347 TABLE 421 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 348 TABLE 422 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 423 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 348 TABLE 424 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 425 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 426 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 427 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 350 TABLE 428 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 350 TABLE 429 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 430 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 351 TABLE 431 SOUTH AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 352 TABLE 432 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 353 TABLE 433 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 434 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR WHOLE SLIDE IMAGING SCANNERS, BY TYPE, 2024–2031 (USD MILLION) 353 TABLE 435 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 436 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 437 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 438 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 355 TABLE 439 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 355 TABLE 440 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET FOR PRE-CLINICAL RESEARCH, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 441 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 356 TABLE 442 REST OF MIDDLE EAST & AFRICA: DIGITAL PATHOLOGY MARKET, BY END USER, 2024–2031 (USD MILLION) 357 TABLE 443 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 358 TABLE 444 DIGITAL PATHOLOGY MARKET: DEGREE OF COMPETITION 363 TABLE 445 DIGITAL PATHOLOGY MARKET: REGION FOOTPRINT 370 TABLE 446 DIGITAL PATHOLOGY MARKET: PRODUCT FOOTPRINT 371 TABLE 447 DIGITAL PATHOLOGY MARKET: APPLICATION FOOTPRINT 372 TABLE 448 DIGITAL PATHOLOGY MARKET: END USER FOOTPRINT 373 TABLE 449 LIST OF STARTUPS/SMES 376 TABLE 450 DIGITAL PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 377 TABLE 451 DIGITAL PATHOLOGY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, APPROVALS 2023–2026 378 TABLE 452 DIGITAL PATHOLOGY MARKET: DEALS, 2023–2026 379 TABLE 453 DIGITAL PATHOLOGY MARKET: EXPANSIONS, 2023–2026 381 TABLE 454 DIGITAL PATHOLOGY MARKET: OTHER DEVELOPMENTS, 2023–2026 381 TABLE 455 DANAHER CORPORATION: COMPANY OVERVIEW 383 TABLE 456 DANAHER CORPORATION: PRODUCTS OFFERED 384 TABLE 457 DANAHER CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JUNE 2026 384 TABLE 458 DANAHER CORPORATION: DEALS, JANUARY 2023−JUNE 2026 385 TABLE 459 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 386 TABLE 460 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 388 TABLE 461 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 389 TABLE 462 HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 390 TABLE 463 HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–JUNE 2026 391 TABLE 464 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 393 TABLE 465 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 394 TABLE 466 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 395 TABLE 467 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2023−JUNE 2026 396 TABLE 468 SECTRA AB: COMPANY OVERVIEW 398 TABLE 469 SECTRA AB: PRODUCTS OFFERED 399 TABLE 470 SECTRA AB: DEALS, JANUARY 2023–JUNE 2026 400 TABLE 471 SECTRA AB: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 402 TABLE 472 HAMAMATSU PHOTONICS K.K.: COMPANY OVERVIEW 403 TABLE 473 HAMAMATSU PHOTONICS K.K.: PRODUCTS OFFERED 404 TABLE 474 HAMAMATSU PHOTONICS K.K.: DEALS, JANUARY 2023–JUNE 2026 405 TABLE 475 QUANTERIX CORPORATION: COMPANY OVERVIEW 407 TABLE 476 QUANTERIX CORPORATION: PRODUCTS OFFERED 408 TABLE 477 QUANTERIX CORPORATION: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 409 TABLE 478 QUANTERIX CORPORATION :DEALS, JANUARY 2023–JUNE 2026 409 TABLE 479 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 410 TABLE 480 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 411 TABLE 481 FUJIFILM HOLDINGS CORPORATION: DEALS, JANUARY 2023–JUNE 2026 412 TABLE 482 HOLOGIC, INC.: COMPANY OVERVIEW 414 TABLE 483 HOLOGIC, INC: PRODUCTS OFFERED 415 TABLE 484 HOLOGIC, INC: PRODUCT APPROVALS, JANUARY 2023–JUNE 2026 416 TABLE 485 3DHISTECH LTD.: COMPANY OVERVIEW 417 TABLE 486 3DHISTECH LTD.: PRODUCTS OFFERED 418 TABLE 487 3DHISTECH LTD.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JUNE 2026 420 TABLE 488 3DHISTECH LTD.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 420 TABLE 489 APOLLO ENTERPRISE IMAGING CORP.: COMPANY OVERVIEW 421 TABLE 490 APOLLO ENTERPRISE IMAGING CORP.: PRODUCTS OFFERED 421 TABLE 491 APOLLO ENTERPRISE IMAGING CORP.: PRODUCT ENHANCEMENTS, JANUARY 2023–JUNE 2026 422 TABLE 492 APOLLO ENTERPRISE IMAGING CORP.: DEALS, JANUARY 2023–JUNE 2026 422 TABLE 493 HURON TECHNOLOGIES INTERNATIONAL INC.: COMPANY OVERVIEW 423 TABLE 494 HURON TECHNOLOGIES INTERNATIONAL INC.: PRODUCTS OFFERED 423 TABLE 495 HURON TECHNOLOGIES INTERNATIONAL INC.: DEALS, JANUARY 2023–JUNE 2026 424 TABLE 496 HURON TECHNOLOGIES INTERNATIONAL INC.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 424 TABLE 497 INDICA LABS, LLC.: COMPANY OVERVIEW 425 TABLE 498 INDICA LABS, LLC: PRODUCTS OFFERED 425 TABLE 499 INDICA LABS, LLC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 426 TABLE 500 INDICA LABS, LLC.: DEALS, JANUARY 2023–JUNE 2026 427 TABLE 501 INDICA LABS, LLC.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 428 TABLE 502 OPTRASCAN: COMPANY OVERVIEW 429 TABLE 503 OPTRASCAN: PRODUCTS OFFERED 429 TABLE 504 OPTRASCAN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JUNE 2026 430 TABLE 505 OPTRASCAN: DEALS, JANUARY 2023–JUNE 2026 430 TABLE 506 GLENCOE SOFTWARE, INC.: COMPANY OVERVIEW 431 TABLE 507 GLENCOE SOFTWARE, INC.: PRODUCTS OFFERED 431 TABLE 508 GLENCOE SOFTWARE, INC.: PRODUCT ENHANCEMENTS, JANUARY 2023–JUNE 2026 432 TABLE 509 AIFORIA: COMPANY OVERVIEW 433 TABLE 510 AIFORIA: PRODUCTS OFFERED 433 TABLE 511 AIFORIA: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 434 TABLE 512 AIFORIA: DEALS, JANUARY 2023–JUNE 2026 434 TABLE 513 AIFORIA: EXPANSIONS, JANUARY 2023–JUNE 2026 436 TABLE 514 PAIGE AI, INC.: COMPANY OVERVIEW 437 TABLE 515 PAIGE AI, INC.: PRODUCTS OFFERED 437 TABLE 516 PAIGE AI, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023–JUNE 2026 438 TABLE 517 PAIGE AI, INC.: DEALS, JANUARY 2023–JUNE 2026 439 TABLE 518 PROSCIA INC.: COMPANY OVERVIEW 442 TABLE 519 PROSCIA INC.: PRODUCTS OFFERED 442 TABLE 520 PROSCIA INC.: PRODUCT ENHANCEMENTS & APPROVALS, JANUARY 2023–JUNE 2026 443 TABLE 521 PROSCIA INC.: DEALS, JANUARY 2023–JUNE 2026 444 TABLE 522 PROSCIA INC.: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 445 TABLE 523 EVIDENT: COMPANY OVERVIEW 446 TABLE 524 EVIDENT: PRODUCTS OFFERED 446 TABLE 525 EVIDENT: PRODUCT LAUNCHES, JANUARY 2023–JUNE 2026 447 TABLE 526 EVIDENT: DEALS, JANUARY 2023–JUNE 2026 447 TABLE 527 RISK ASSESSMENT: DIGITAL PATHOLOGY MARKET 471 FIGURE 1 MARKET SCENARIO 47 FIGURE 2 GLOBAL DIGITAL PATHOLOGY MARKET, 2024–2031 47 FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DIGITAL PATHOLOGY MARKET, 2023–2026 48 FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF DIGITAL PATHOLOGY MARKET 49 FIGURE 5 HIGH-GROWTH SEGMENTS IN DIGITAL PATHOLOGY MARKET, 2026–2031 50 FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DIGITAL PATHOLOGY MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51 FIGURE 7 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES IS INCREASING PATHOLOGY TESTING VOLUME TO DRIVE MARKET GROWTH 52 FIGURE 8 HARDWARE IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 53 FIGURE 9 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 54 FIGURE 10 DIGITAL PATHOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 11 GLOBAL CANCER INCIDENCE, 2008−2030 58 FIGURE 12 FDA-APPROVED PERSONALIZED MEDICINES, 2015−2024 68 FIGURE 13 DIGITAL PATHOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 75 FIGURE 14 DIGITAL PATHOLOGY MARKET: VALUE CHAIN ANALYSIS 78 FIGURE 15 ECOSYSTEM ANALYSIS 80 FIGURE 16 REVENUE SHIFT IN DIGITAL PATHOLOGY MARKET 86 FIGURE 17 RECENT FUNDING OF PLAYERS IN DIGITAL PATHOLOGY MARKET 87 FIGURE 18 PATENT PUBLICATION TRENDS IN DIGITAL PATHOLOGY MARKET, 2015–2026 99 FIGURE 19 JURISDICTION AND TOP APPLICANT ANALYSIS FOR DIGITAL PATHOLOGY MARKET 100 FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DIGITAL PATHOLOGY MARKET (JANUARY 2015–JUNE 2026) 101 FIGURE 21 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING DIGITAL PATHOLOGY 105 FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEM 107 FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 124 FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 126 FIGURE 25 NORTH AMERICA: DIGITAL PATHOLOGY MARKET SNAPSHOT 198 FIGURE 26 ASIA PACIFIC: DIGITAL PATHOLOGY MARKET SNAPSHOT 264 FIGURE 27 DIGITAL PATHOLOGY MARKET: REVENUE ANALYSIS OF TOP LISTED/PUBLIC PLAYERS, 2021–2025 (USD MILLION) 361 FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 362 FIGURE 29 BRAND COMPARISON 365 FIGURE 30 EV/EBITDA OF KEY VENDORS 366 FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS 366 FIGURE 32 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 368 FIGURE 33 DIGITAL PATHOLOGY MARKET: COMPANY FOOTPRINT 369 FIGURE 34 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 375 FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 383 FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 389 FIGURE 37 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2025) 394 FIGURE 38 SECTRA AB: COMPANY SNAPSHOT (2025) 399 FIGURE 39 HAMAMATSU PHOTONICS K.K.: COMPANY SNAPSHOT (2025) 404 FIGURE 40 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2024) 408 FIGURE 41 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025) 411 FIGURE 42 HOLOGIC, INC.: COMPANY SNAPSHOT (2025) 415 FIGURE 43 RESEARCH DESIGN 456 FIGURE 44 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 461 FIGURE 45 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 462 FIGURE 46 BOTTOM-UP APPROACH 463 FIGURE 47 TOP-DOWN APPROACH 464 FIGURE 48 CAGR PROJECTIONS FROM DROC ANALYSIS OF DIGITAL PATHOLOGY MARKET 465 FIGURE 49 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 466 FIGURE 50 DATA TRIANGULATION METHODOLOGY 469

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們